awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q53786874-5FEA7AFE-8388-4233-991E-FDE34809F346
Q53786874-5FEA7AFE-8388-4233-991E-FDE34809F346
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53786874-5FEA7AFE-8388-4233-991E-FDE34809F346
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
P2860
Q53786874-5FEA7AFE-8388-4233-991E-FDE34809F346
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53786874-5FEA7AFE-8388-4233-991E-FDE34809F346
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ecdb0433a18e89e9d2969dae90443410f832abbd
P2860
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.